This seminar explores the impactful role of artificial intelligence and deep learning in various bioinformatics domains through two presentations. Dr. Iana Safonova, focusing on immunogenomics, elucidates the complexities of adaptive immunity, particularly the vast diversity of antibodies and T-cell receptors, and the challenges in cross-species comparison due to rapid genomic evolution and structural variations. She highlights promising AI/ML applications in immune feature representation, pattern discovery, antibody specificity prediction, and structural modeling. Dr. Pitson subsequently delves into mass spectrometry-based proteomics, detailing its methodological principles, from isotopic distributions to peptide fragmentation and identification. He illustrates how machine learning significantly enhances MS method development—improving target-decoy separation, chromatography prediction, and fragment intensity prediction—and empowers applications such as immunopeptide predictions vital for personalized cancer vaccines. Both speakers advocate for a balanced, biologically informed application of AI/ML, urging for foundational understanding and interpretability over blind reliance on complex models, while addressing critical challenges like PTM-aware structural predictions and comprehensive antibody repertoire sequencing.
Summarizing the Bioinformatics Club Seminars on AI/Deep Learning
0:00 Seminar Introduction: The third "Bioinformatics Club seminars" meeting discusses the current and future impact of AI/deep learning on bioinformatics, particularly on a bioinformatician's daily routine.
2:15 Speaker 1: Dr. Iana Safonova (Immunogenomics): Introduces herself as a computational biologist from Penn State, emphasizing the undeniable opportunities machine learning offers, even for those not primarily trained in it.
4:13 Adaptive Immunity: A Major Challenge for Biology and AI: Explains that while innate immunity is relatively consistent, the immense, undersampled diversity of adaptive immunity (B cells/antibodies, T cells/receptors) makes understanding disease susceptibility difficult, marking it as a key area for machine learning intervention.
6:20 Generating Antibody Diversity: Describes how antibodies achieve vast diversity through somatic V(D)J recombination and rapid, evolutionary-like maturation processes, leading to highly individualized immune repertoires with near-zero overlap between individuals, complicating population-level studies.
10:14 Genomic Complexity Hinders Cross-Species Comparison: The genomics of immune loci are highly complex, exhibiting rapid evolution and extensive structural variations. This makes direct gene-level comparisons across species challenging (e.g., humans vs. mice), impeding the discovery of unique immune adaptations.
17:20 Structural Variations Drive Rapid Evolution: Dot plot analysis of immunoglobulin heavy chain loci reveals that tandem repeats and complex structural variations are significant drivers of rapid, species-specific immune system evolution, suggesting a role for AI in detecting these intricate genomic patterns.
23:29 AI's Future in Immunogenomics: Dr. Safonova outlines key applications for ML: developing better feature representations for diverse immune responses, uncovering hidden patterns in immune genes, predicting antibody specificity, and improving antibody 3D structure prediction (where current tools like AlphaFold fall short), with antibody drug optimization being a particularly fast-moving area.
28:00 AlphaFold Limitations: Antibodies pose a challenge for AlphaFold due to their unique amino acid composition, antigen-driven structural shaping, and the current structural database's bias and limited size.
29:28 LLMs in Scientific Workflows: Sees a transformative role for LLMs in automating programming tasks (e.g., script pipelines) and routine scientific writing, advocating for their use as tools that, when curated, can enhance efficiency.
34:00 Evolutionary Drivers: Explains that genetic bottlenecks and differing evolutionary trajectories contribute to the species-specific divergence and structural complexity observed in immune loci.
39:35 Immunogenomics Barriers: Highlights that a lack of fundamental biological understanding, historical data standardization issues, and germline diversity are primary obstacles to large-scale immunogenomics, emphasizing ML's role as a tool rather than a "crystal ball."
43:06 Speaker 2: Dr. Pitson (Mass Spectrometry-Based Proteomics): Introduces his focus on how machine learning is advancing mass spectrometry (MS) in proteomics, crucial for studying proteins, their post-translational modifications (PTMs), and behavior.
44:43 The Importance of Proteomics and Mass Spectrometry: Proteins integrate vital biological information (DNA, RNA, PTMs, localization), making their study crucial. Mass spectrometry is presented as a versatile, uniform method for analyzing proteins and other biomolecules, capable of detecting multiple isotopic peaks for a single peptide.
50:00 Detecting Post-Translational Modifications (PTMs): PTMs are highly diverse and critical for protein function. Tandem MS allows their detection by fragmenting peptides and observing characteristic mass shifts.
53:01 Shotgun Proteomics Workflow: Details the process from protein digestion into peptides, chromatographic separation, electrospray ionization, and mass spectrometry analysis. Peptide sequencing involves de novo assembly or, more commonly, database matching against theoretical spectra.
57:58 ML for MS Method Development – Current Applications: Machine learning significantly improves several core MS processes:
59:11 Target-Decoy Separation: Enhances control over False Discovery Rate (FDR) in peptide identification, especially with numerous features.
1:02:51 Chromatography Prediction: Accurately predicts peptide retention times and ion mobilities, increasingly utilizing protein language models.
1:03:57 Fragment Intensity Prediction: Predicts peptide fragment intensities, a complex physicochemical problem, and is now a standard component in proteomics pipelines.
1:06:22 ML for MS Method Development – Hot Topics & Challenges:
1:06:53 Predicting Biases: Addresses the challenge of predicting and correcting for various biases (protease, solubility, ionization) that cause quantification variability, requiring advanced ML models beyond simple application.
1:09:27 End-to-End De Novo Sequencing: Explores using transformer models for direct peptide sequencing from raw MS/MS spectra, with a focus on models capable of handling and expressing uncertainty.
1:10:51 Spectra Foundation Models: Inspired by LLMs, these models aim to predict missing spectral peaks (mass or intensity) based on context, promising improved interpretation without preprocessing biases.
1:12:01 ML for MS Applications: Highlights ML's role in improving overall peptide identification, especially in Data-Independent Acquisition (DIA) proteomics, and enhancing immunopeptide representation and predictions. Advanced statistical methods are increasingly used for differential expression analysis.
1:12:57 Personalized Cancer Vaccines: ML, combined with MS, is crucial for predicting tumor-specific neoantigens (HLA-presented peptides), paving the way for personalized cancer vaccinations within the next decade.
1:15:15 Grand Challenges in Proteomics: Identifies key future directions:
1:15:32 Protein-Protein Interaction Predictions: Leveraging MS data with ML.
1:16:00 PTM-Aware Structure Predictions: Understanding how PTMs affect and are affected by protein 3D structure (e.g., phosphorylation sites often found in intrinsically disordered regions).
1:16:16 Antibody Repertoire Sequencing: Developing methods to comprehensively sequence all antibodies in a blood sample to monitor immune changes after events like vaccination.
1:21:48 Philosophical Thoughts: Advises a pragmatic approach to ML, starting with simpler models, considering computational resources, and prioritizing biological interpretation and validation over black-box solutions.
1:25:16 LLMs in Proteomics: Sees protein language models as effective feature extractors for various tasks but advises caution for basic statistical operations.
1:27:38 ML for Neoantigen Prediction: Affirms that ML is highly effective for predicting tumor-specific HLA peptides due to their short sequences, improving identification quality.
1:29:05 Structure Affecting MS Visibility: Acknowledges that PTMs and protein structure profoundly and non-linearly affect peptide detectability, solubility, and fragmentation in MS, posing a significant challenge for quantitative PTM studies.